DENV Precursor Peptide Specific Neutra™ Antibody Products

Are you facing challenges in developing broadly protective dengue therapies or encountering cross-reactivity issues with current antibody candidates? Creative Biolabs' DENV Precursor Peptide Specific Neutra™ Antibody Products empower your research with high-specificity, neutralizing antibodies generated through advanced epitope-focused design, enabling precise targeting of conserved viral elements to overcome serotype-specific limitations and accelerate antiviral development.

Introduction to DENV Precursor Peptide

The Dengue virus (DENV) precursor peptide, or pr peptide, is a critical viral element derived from the proteolytic processing of the polyprotein. It constitutes a segment of the precursor membrane (prM) protein, which is essential for the morphogenesis and infectivity of immature dengue virions. The pr peptide is cleaved from the prM protein by host furin protease during viral maturation. This cleavage event is a key regulatory step, triggering conformational changes that render the mature virion infectious. The sequence of the pr peptide is relatively conserved across DENV serotypes compared to the highly variable envelope protein, making it an attractive target for broad-spectrum interventions.

• Structural Insights

In the immature virion, the pr peptide acts as a chaperone, capping the fusion loop of the envelope (E) protein to prevent premature fusion. Structural studies, including cryo-EM, reveal that the pr peptide maintains the E protein in a metastable state until cleavage occurs. This intimate structural role makes it a critical determinant of viral assembly and entry.

Fig.1 Schematic depiction of the DENV genome and its polyprotein precursor for viral proteins.¹

• Resistance and Signaling Pathways

Antibody pressure targeting the E protein can drive the selection of escape mutants. Targeting the structurally constrained pr peptide, however, may impose higher fitness costs on the virus, potentially reducing the emergence of resistant variants. Antibodies against the pr peptide can interfere with the essential furin cleavage step, disrupting the maturation cascade and producing non-infectious particles.

• Clinical Impact

Dengue virus infection causes a spectrum of diseases, from self-limiting dengue fever to severe dengue (dengue hemorrhagic fever/shock syndrome). The antibody-dependent enhancement (ADE) phenomenon, where sub-neutralizing antibodies from a prior infection can exacerbate a secondary heterotypic infection, remains a major challenge in vaccine and therapeutic development.

• Antibodies Against DENV Precursor Peptide
  Neutralizing antibodies targeting the pr peptide offer a distinct strategic advantage. They can:
  • Block the essential prM cleavage, halting virion maturation.
  • Provide broader serotype cross-reactivity by targeting a more conserved region.
  • Potentially mitigate ADE risk by binding epitopes less prone to inducing enhancing antibodies.
  • Serve as critical reagents for studying viral maturation dynamics and for detecting immature/partially mature viral particles in research and clinical samples.

Applications of Anti-DENV Precursor Peptide Neutralizing Antibodies

Fig.2 Assessment of maturation status, infectivity, and mAb-mediated neutralization of viral stocks.²

• Therapeutic Development for Broad-Spectrum Protection

Our high-affinity anti-pr peptide antibodies are engineered to neutralize multiple DENV serotypes by blocking the essential maturation cleavage. In preclinical models, such antibodies have demonstrated efficacy in reducing viremia and preventing severe disease outcomes by generating a pool of non-infectious viral particles. This approach directly targets a bottleneck in the viral life cycle, offering a promising path toward therapies that circumvent serotype-specific escape and ADE concerns associated with traditional envelope-targeting antibodies.

• Advanced Virological Research and Assay Development

These antibodies are indispensable tools for dissecting the dengue virus assembly and maturation pathway. Applications include immunofluorescence and electron microscopy to visualize prM processing and virion morphogenesis, as well as Western blot and ELISA to differentiate between mature and immature viral particles in cell culture supernatants or patient sera. This enables a precise study of viral fitness and the impact of maturation inhibitors.

• Diagnostic and Vaccine Efficacy Evaluation

Antibodies specific to the pr peptide can be utilized in diagnostic assays to detect the presence of immature virions, which may correlate with infection stages or specific disease states. Furthermore, they serve as critical reagents in vaccine studies to quantify the induction of maturation-blocking antibodies, a valuable correlate of protection that may predict broader vaccine efficacy across serotypes.

Our Anti-DENV Precursor Peptide Neutralizing Antibodies

Creative Biolabs delivers rigorously validated antibody solutions designed for the highest standards of dengue research:

• High Specificity and Cross-Reactivity: Antibodies are selected for precise targeting of conserved conformational epitopes on the pr peptide, ensuring minimal off-target binding and enhanced cross-serotype recognition.
• Validated Neutralizing Function: Each batch is functionally validated in vitro using standardized viral neutralization assays to confirm potent inhibition of DENV infectivity.
• Multiple Application Formats: Optimized for consistent performance in demanding applications, including neutralization assays, ELISA, Western blot, immunofluorescence, and immunohistochemistry.
• Tailored for Therapeutic Discovery: Ideal for screening, lead optimization, and mechanism-of-action studies in antibody and antiviral drug development pipelines.

Creative Biolabs is your dedicated partner in advancing infectious disease research. Our DENV Precursor Peptide Specific Neutra™ Antibody Products embody our commitment to providing scientists with reliable, high-performance tools that accelerate discovery from bench to bedside. Contact our scientific team today to learn more and discuss your specific project requirements.

References

1. Alves, Ada Maria Barcelos, Simone Morais Costa, and Paolla Beatriz Almeida Pinto. "Dengue Virus and Vaccines: How Can DNA Immunization Contribute to This Challenge?" Frontiers in Medical Technology 3 (2021): 640964. Distributed under Open Access license CC BY 4.0, without modification. https://doi.org/10.3389/fmedt.2021.640964
2. Bos, Sandra, et al. "Protection against symptomatic dengue infection by neutralizing antibodies varies by infection history and infecting serotype." Nature Communications 15.1 (2024): 382. Distributed under Open Access license CC BY 4.0, without modification. https://doi.org/10.1038/s41467-023-44330-8